scholarly journals Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy

2013 ◽  
Vol 6 (6) ◽  
pp. 742-IN34 ◽  
Author(s):  
Nicole R. Parker ◽  
Nelson Correia ◽  
Brendan Crossley ◽  
Michael E. Buckland ◽  
Viive M. Howell ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Clinical Outcome ◽  
Primary Glioblastoma ◽  
Adjuvant Temozolomide ◽  
Unfavorable Clinical Outcome ◽  
Temozolomide Chemotherapy

scholarly journals The therapeutic potential of curcumin for the treatment of glioblastoma multiforme

2020 ◽  
Vol 7 (1) ◽  
pp. 8-16
Author(s):  
T. I. Kushnir ◽  
N. E. Arnotskaya ◽  
I. A. Kudryavtsev ◽  
V. E. Shevchenko
Keyword(s):  
Cell Cycle ◽  
Glioblastoma Multiforme ◽  
Therapeutic Agent ◽  
Therapeutic Potential ◽  
Chemotherapeutic Agents ◽  
Complementary Treatment ◽  
Adjuvant Temozolomide ◽  
Median Survival Rate ◽  
Temozolomide Chemotherapy ◽  
Primary Malignant Brain Tumor

Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly type of primary malignant brain tumor, with a patien’s median survival rate ranging from 12 to 15 months. Over the last fifteen years, the treatment for GBM has included maximal safe surgical resection with combination radiotherapy and adjuvant temozolomide chemotherapy. The low efficacy of mentioned therapies has forced researchers to explore an appropriate alternative or complementary treatment for GBM. It has been shown that curcumin has therapeutic potentials to fight against GBM via affecting on cell proliferation, apoptosis, cell cycle, invasion and angiogenesis pathways. In addition, curcumin possess a synergistic impact with chemotherapeutic agents. Herein, we summarized the current findings on curcumin as potential therapeutic agent in the treatment of GBM.

AB0510 Predicting Factors of Unfavorable Clinical Outcome in Lupus Nephritis

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 975.2-975
Author(s):  
D. Kishimoto ◽  
Y. Kunishita ◽  
R. Kamiyama ◽  
K. Minegishi ◽  
M. Hama ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Clinical Outcome ◽  
Predicting Factors ◽  
Unfavorable Clinical Outcome

scholarly journals CTNI-30. THERAPEUTIC EFFECTS OF RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE VERSUS RADIOTHERAPY WITH CONCOMITANT TEMOZOLOMIDE ALONE IN CHILDREN WITH DIPG: A SINGLE-CENTER EXPERIENCE WITH 82 CASES

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii49-ii49
Author(s):  
Mingyao Lai ◽  
Juan Li ◽  
Qingjun Hu ◽  
Jiangfen Zhou ◽  
Shaoqun Li ◽  
...  
Keyword(s):  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Disease Recurrence ◽  
Diffuse Intrinsic Pontine Glioma ◽  
Hematological Toxicity ◽  
Therapeutic Effects ◽  
Single Center Experience ◽  
Adjuvant Temozolomide ◽  
Temozolomide Chemotherapy

Abstract OBJECTIVE To retrospectively analyze the therapeutic effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with concomitant temozolomide alone for pediatric diffuse intrinsic pontine glioma (DIPG), and to evaluate the value of temozolomide in the treatment of pediatric DIPG. METHODS The clinical data of children with confirmed DIPG in Guangdong Sanjiu Brain Hospital between January 1, 2010 and December 30, 2019 were collected. The inclusive criteria included (1) receiving a total radiotherapy dose of 54 Gy in 27 fractions, (2) treated with concomitant temozolomide chemotherapy, and (3) with or without adjuvant temozolomide chemotherapy. RESULTS A total of 82 pediatric patients were eligible for the study, with a median age of 7 years (range 2–16 years). The median follow-up was 8.6 months (range 2–28 months) and the median survival time was 9.4 months. The median survival time of 66 patients treated with radiotherapy with concomitant and adjuvant temozolomide was 9.8 months, longer than 7.5 months of the other 16 patients treated with radiotherapy with concomitant temozolomide alone, with statistical differences (P=0.010). Moreover, bevacizumab and nimotuzumab didn’t bring survival benefits to patients with disease recurrence or progression. Hematological toxicity (Grade IV) was not found. CONCLUSION Radiotherapy with concomitant and adjuvant temozolomide prolongs the survival time of children with DIPG.

scholarly journals Advances in Immunotherapy for Glioblastoma Multiforme

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Boyuan Huang ◽  
Hongbo Zhang ◽  
Lijuan Gu ◽  
Bainxin Ye ◽  
Zhihong Jian ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Cancer Vaccines ◽  
Immune Checkpoint Blockade ◽  
First Line ◽  
Specific Cancer ◽  
Personalized Approach ◽  
Poor Outcomes ◽  
Temozolomide Chemotherapy ◽  
Primary Malignant Brain Tumor ◽  
First Line Treatment

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests that advances in antigen-specific cancer vaccines and immune checkpoint blockade in other advanced tumors may provide an appealing promise for immunotherapy in glioma. The future of therapy for GBM will likely incorporate a combinatorial, personalized approach, including current conventional treatments, active immunotherapeutics, plus agents targeting immunosuppressive checkpoints.

Association between HbA1C (glycated hemoglobin) and clinical outcomes in patients with subarachnoid hemorrhage after neuro-intervention

2021 ◽  
Vol 18 ◽  
Author(s):  
Chan Woong Park ◽  
Ho Jun Yi ◽  
Dong Hoon Lee ◽  
Jae Hoon Sung
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Clinical Outcome ◽  
Clinical Outcomes ◽  
Glycated Hemoglobin ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Roc Curve Analysis ◽  
Optimal Cutoff ◽  
Cutoff Value ◽  
Unfavorable Clinical Outcome ◽  
High Hba1c

Objective: Our study investigated the association between level of HbA1c (glycated hemoglobin) at admission and the prognosis of aneurysmal subarachnoid hemorrhage (SAH). Methods: A total of 510 patients treated with neuro-intervention for aneurysmal SAH and with data for admission HbA1c (glycated hemoglobin) were included. Favorable clinical outcome was defined as Modified Rankin Scale (mRS) score of 0–2 at 3 months. Receiver operating characteristic (ROC) curve analysis was used to identify the optimal cutoff value of HbA1C for unfavorable clinical outcomes. Logistic regression was used to evaluate the association between HbA1C level and outcomes. Results: The optimal cutoff value of HbA1C was identified as 6.0% (P < 0.001), and patients with a high HbA1C (≥ 6.0%) had a lower prevalence of favorable clinical outcomes than patients with low HbA1C (< 6.0%) (P < 0.001). High HbA1C (≥ 6.0%) was independently associated with unfavorable clinical outcome (OR 2.84; 95% CI: 1.52-5.44; P = 0.004). The risk of unfavorable clinical outcome was significantly increased in patients with HbA1C (≥ 7.0%, < 8%) and HbA1C (≥ 8.0%) compared with lower baseline HbA1C (≥ 6.0%, < 7%) values (OR 2.17; 95% CI: 1.87-5.13; P = 0.011 and OR 4.25; 95% CI: 3.17-8.41; P = 0.005). Conclusions: Our study showed that HbA1C could be an independent predictor of worse outcome following neuro-intervention for aneurysmal SAH. High HbA1C (≥ 6.0%) was associated with unfavorable clinical outcome, and gradual elevation of HbA1C contributed to an increase in the risk of worse clinical outcome after SAH.

scholarly journals Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children

2015 ◽  
Vol 3 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Rakesh Jalali ◽  
Anupam Rishi ◽  
Jayant S. Goda ◽  
Epari Sridhar ◽  
Mamta Gurav ◽  
...  
Keyword(s):  
Overall Survival ◽  
Clinical Outcome ◽  
Labeling Index ◽  
Molecular Profile ◽  
Mgmt Methylation ◽  
P53 Overexpression ◽  
P53 Expression ◽  
Egfr Amplification ◽  
Adjuvant Temozolomide ◽  
Mib 1

Abstract Background Glioblastoma (GBM) in children is rare. Pediatric GBM have a distinct molecular profile as compared to adult GBM. There are relatively few studies of pediatric GBMs and no standard of care on adjuvant therapy. We aimed to evaluate the clinical outcome and molecular profile of pediatric GBM. Methods and Materials Between 2004 and 2013, 66 consecutive children with histologically proven GBM were identified from our database. The majority of the children underwent maximal safe resection followed by focal radiotherapy with concurrent and adjuvant temozolomide. Immunohistochemical staining was performed for p53, MIB-1 labeling index, MGMT overexpression, and EGFR amplification and isocitrate dehydrogenase (IDH1) R132H point mutation. Survival and impact of possible prognostic factors on outcomes were analyzed. Result Median survival was 15 months. The overall survival rate at 1 year was 62%, at 2 years was 30%, and at 3 years was 27%. Patients with thalamic tumors (P &lt; .001), incompletely resected tumors (P &lt; .00001), and tumors with MIB-1 labeling index &gt;25% (P &lt; .002) had poor overall survival rates. p53 was overexpressed in 74% of patients, MGMT promoter methylation was seen in 37% of patients, IDH1 mutation was seen in 4% of patients, and no patients had EGFR amplification. MGMT methylation and p53 overexpression did not impact survival. Conclusions Clinical outcome of pediatric GBM is similar to that reported for adult GBM. The frequency of p53 overexpression is higher than in adult GBM, while MGMT methylation, IDH1 mutations and EGFR amplification is lower than in adult GBM. MGMT methylation and p53 expression status do not have any prognostic significance.

Sign in / Sign up

Export Citation Format

Share Document